Academic Journal
Q1Breast Cancer Research and Treatment
About Breast Cancer Research and Treatment
About Breast Cancer Research and Treatment
Breast Cancer Research and Treatment is a peer-reviewed scholarly journal published by Springer (United States). It focuses on Q1. Publication coverage spans 1981-2026.
Key indicators: ISSN 0167-6806, 1573-7217; H-index 189.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (189): Exceptionally high — 189 articles have each been cited at least 189 times. This indicates deep, sustained influence in the field.
Publishing in Breast Cancer Research and Treatment
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q1. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Breast Cancer Research and Treatment?
0167-6806, 1573-7217.
Who publishes Breast Cancer Research and Treatment?
Springer.
What are Breast Cancer Research and Treatment's metrics?
H-index 189.
Is Breast Cancer Research and Treatment peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Breast Cancer Treatment Studies; Estrogen and related hormone effects; HER2/EGFR in Cancer Research; Breast Lesions and Carcinomas; BRCA gene mutations in cancer; Cancer Risks and Factors.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
4,190.00 USD; 3,190.00 EUR; 2,690.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
A dermal backflow atlas of lymphatic dysfunction in breast cancer-related lymphedema with machine learning-based stage prediction
Lalida Sutejitsiri, Hiroo Suami, Poul M F Nielsen, Anthony R J Phillips et al.
2026-10 · DOI: 10.1007/s10549-026-08093-2Brain-only metastatic breast cancer as a distinct clinical entity: evidence from national and institutional cohorts with implications for radiation therapy
Marshall Harrell, Tugce Kutuk, Yevgeniya Gokun, Rituraj Upadhyay et al.
2026-10 · DOI: 10.1007/s10549-026-08092-3Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability
Shivahamy Maheswaran, Aylin S. Dedeoglu, Andrzej Niemierko, Rachel O. Abelman et al.
2026-10 · DOI: 10.1007/s10549-026-08079-0Implementation and evaluation of the Routine Assessment and Integration of Screening for Employment (RAISE) program in adults with metastatic breast cancer
Laura C. Pinheiro, Caroline Zeng, Darima Dorzhieva, Lovely Joseph et al.
2026-10 · DOI: 10.1007/s10549-026-08089-yCirculating tumour DNA and its clinical relevance in predicting progression-free survival and overall survival in patients with advanced breast cancer: a systematic review and meta-analysis
Cæcilie Ottosen, Ea Kragelund, Mette Abildgaard Pedersen, Vivi Quoc Nguyen et al.
2026-10 · DOI: 10.1007/s10549-026-08087-0Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force “Dermatology for Cancer Patients” and pharmacovigilance analysis
Ioannis-Alexios Koumprentziotis, Alexander Cawley, Elliot Ewig, Alexandre O. Gérard et al.
2026-10 · DOI: 10.1007/s10549-026-08090-5HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer
Payu Raval, Qingqing Ding, Puneet Singh, Alaaeddin Alrohaibani et al.
2026-10 · DOI: 10.1007/s10549-026-08088-zGeographic access to triple negative breast cancer clinical trials: are trials located near patients?
Laura Burns Amin, M. Kelsey Kirkwood, Laura A. Levit, Erin P. Balogh et al.
2026-10 · DOI: 10.1007/s10549-026-08084-3Ki-67 expression and rates of pathologic complete response in T1cN0M0 triple-negative breast cancer: a national cancer database analysis
Andrew Venardi, Fatemeh Shojaeian, Sophia Diaz, Calvin R. Schuster et al.
2026-10 · DOI: 10.1007/s10549-026-08086-1A retrospective, observational cohort study of treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States following endocrine therapy
Joyce O’Shaughnessy, MK Rehnquist, Natalia Sadetsky, Wendy Verret et al.
2026-10 · DOI: 10.1007/s10549-026-08075-4Recovery of ovarian function after chemotherapy in premenopausal women with breast cancer: a systematic review and meta-analysis
Phi Y. Huynh, Binh V. Tran, Vinh T. Ngo, Tu T. Tran et al.
2026-10 · DOI: 10.1007/s10549-026-08083-4Equivalent survival in targeted axillary dissection compared to axillary lymph node dissection in patients with node positive breast cancer receiving neoadjuvant chemotherapy
Callie Hlavin, Zainab Balogun, Danielle R. Lavage, Michael S. Cowher et al.
2026-10 · DOI: 10.1007/s10549-026-08078-1Trends in contralateral prophylactic mastectomy and genetic testing in the era of new society guidelines
Anna M. Reagan, Christina R. Rutherford, Saranya Prathibha, Brittany E. Levy et al.
2026-10 · DOI: 10.1007/s10549-026-08073-6Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer – results from the phase II DETECT IVb trial
F. Schochter, T.W.P. Friedl, H. Schäffler, F. Meier-Stiegen et al.
2026-10 · DOI: 10.1007/s10549-026-08069-2Integrin α2 (CD49b) blockade remodels the tumor immune microenvironment and enhances anti-PD-L1 therapy in 4T1 breast cancer model
Ibrahim Ragab Eissa, Yongtao Wang, Kenneth K. Tanabe
2026-10 · DOI: 10.1007/s10549-026-08077-2Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer
Ali Sanjari Moghaddam, Zhirui Deng, Susan M. Sereika, Maryam Habib et al.
2026-10 · DOI: 10.1007/s10549-026-08067-4Contemporary therapy for small node-negative triple-negative breast cancer: a retrospective cohort study
Brian Lee, Bethania Santos, Heather McArthur, Alexis LeVee et al.
2026-10 · DOI: 10.1007/s10549-026-08074-5Association between cumulative symptom burden and cognitive impairment among breast cancer survivors: a cross-sectional study
Xiaotong Li, Kaitlin Lampson, Kevin T. Liou, Yuelin Li et al.
2026-10 · DOI: 10.1007/s10549-026-08064-7Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study
Jingze Liu, Linxiaoxiao Ding, Jiayi Wang, Tao Chen et al.
2026-09 · DOI: 10.1007/s10549-026-08070-9Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes
Matthew R. Kroll, Mary C. Schroeder, Joan M. Neuner, Brahmendra R. Viyyuri et al.
2026-09 · DOI: 10.1007/s10549-026-08071-8Reviews
Community Reviews
Version History
October 9, 2026 at 7:42 pm
September 25, 2026